Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin
- PMID: 15364449
- DOI: 10.1016/j.vaccine.2004.03.057
Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin
Abstract
Vaccinia vaccines have become important vectors for antigen-specific immunotherapy. Calreticulin has been shown to enhance MHC class I presentation of linked peptide/protein and may be useful for antigen-specific cancer treatment. An innovative vaccine administering antigen linked to calreticulin via a vaccinia vector may generate a potent antigen-specific antitumor response. We tested the efficacy of linking calreticulin (CRT) to model antigen human papilloma virus type 16 (HPV-16) E7 in the context of a vaccinia vaccine (Vac-CRT/E7). Intraperitoneal vaccination of C57BL/6 mice with Vac-CRT/E7 led to a dramatic increase in E7-specific IFN-gamma-secreting CD8+ T cells and a potent antitumor effect against E7-expressing tumors compared to immunization with Vac-E7 or Vac-CRT. When compared to other chimeric vaccinia vaccines employing various intracellular targeting strategies previously developed in our lab, Vac-CRT/E7 elicited the highest number of E7-specific CD8+ T cells. Thus, vaccination with vaccinia expressing CRT linked to a tumor antigen may represent an advantageous strategy for cancer immunotherapy.
Similar articles
-
Comparison of HPV DNA vaccines employing intracellular targeting strategies.Gene Ther. 2004 Jun;11(12):1011-8. doi: 10.1038/sj.gt.3302252. Gene Ther. 2004. PMID: 14985791
-
Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen.J Clin Invest. 2001 Sep;108(5):669-78. doi: 10.1172/JCI12346. J Clin Invest. 2001. PMID: 11544272 Free PMC article.
-
Recombinant DNA vaccines protect against tumors that are resistant to recombinant vaccinia vaccines containing the same gene.Gene Ther. 2001 Jan;8(2):128-38. doi: 10.1038/sj.gt.3301370. Gene Ther. 2001. PMID: 11313782
-
Poxviruses as vaccine vectors.Comp Immunol Microbiol Infect Dis. 2003 Oct;26(5-6):343-55. doi: 10.1016/S0147-9571(03)00019-5. Comp Immunol Microbiol Infect Dis. 2003. PMID: 12818621 Review.
-
Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer.Vaccine. 2001 Mar 21;19(17-19):2549-56. doi: 10.1016/s0264-410x(00)00488-6. Vaccine. 2001. PMID: 11257391 Review.
Cited by
-
Chitosan hydrogel containing GMCSF and a cancer drug exerts synergistic anti-tumor effects via the induction of CD8+ T cell-mediated anti-tumor immunity.Clin Exp Metastasis. 2009;26(3):179-87. doi: 10.1007/s10585-008-9228-5. Epub 2008 Dec 14. Clin Exp Metastasis. 2009. PMID: 19082918
-
Targeting and retention of HPV16 E7 to the endoplasmic reticulum enhances immune tumour protection.J Cell Mol Med. 2010 Apr;14(4):890-4. doi: 10.1111/j.1582-4934.2009.00934.x. Epub 2009 Oct 10. J Cell Mol Med. 2010. PMID: 19818090 Free PMC article.
-
Lymph node-targeted immunotherapy mediates potent immunity resulting in regression of isolated or metastatic human papillomavirus-transformed tumors.Clin Cancer Res. 2009 Oct 1;15(19):6167-76. doi: 10.1158/1078-0432.CCR-09-0645. Epub 2009 Sep 29. Clin Cancer Res. 2009. PMID: 19789304 Free PMC article.
-
Therapeutic human papillomavirus vaccines: current clinical trials and future directions.Expert Opin Biol Ther. 2008 Apr;8(4):421-39. doi: 10.1517/14712598.8.4.421. Expert Opin Biol Ther. 2008. PMID: 18352847 Free PMC article. Review.
-
Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice.Cancer Immunol Immunother. 2007 Jul;56(7):997-1007. doi: 10.1007/s00262-006-0247-2. Epub 2006 Dec 5. Cancer Immunol Immunother. 2007. PMID: 17146630 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous
